Submitted by Biotechman and Optiondragon
Earlier this week, Biogen Idec Inc. and partner Elan Corp forecasted that by 2010 it would have 100,000 patients taking Tysabri, which costs $29,400 per year. Biogen believes that sales growth in 2008 will be mostly coming from Tysarbi. They also said recently that as of the end of September there have […]



![[Most Recent Charts from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_6.gif)
![[Most Recent Charts from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_6.gif)











